Heska (NASDAQ:HSKA)‘s stock had its “buy” rating reissued by research analysts at Raymond James Financial in a note issued to investors on Monday.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity started coverage on Heska in a research report on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price on the stock. Benchmark reaffirmed a “buy” rating and issued a $120.00 target price (up previously from $106.00) on shares of Heska in a research report on Wednesday, August 9th. B. Riley reaffirmed a “hold” rating and issued a $96.50 target price on shares of Heska in a research report on Friday, October 27th. Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, BidaskClub downgraded Heska from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $113.30.

Shares of Heska (NASDAQ:HSKA) traded down $0.39 during midday trading on Monday, reaching $85.93. The company’s stock had a trading volume of 70,500 shares, compared to its average volume of 82,289. The firm has a market capitalization of $625.25, a P/E ratio of 45.19, a PEG ratio of 2.30 and a beta of 0.75. Heska has a 1 year low of $65.33 and a 1 year high of $115.00.

Heska (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The firm had revenue of $31.40 million for the quarter, compared to the consensus estimate of $36.10 million. During the same quarter in the previous year, the business earned $0.45 earnings per share. The business’s revenue was down 6.0% compared to the same quarter last year. equities analysts anticipate that Heska will post 2.03 earnings per share for the current fiscal year.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the sale, the insider now directly owns 106,771 shares in the company, valued at $9,304,024.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in HSKA. Teachers Advisors LLC raised its position in Heska by 11.6% during the 1st quarter. Teachers Advisors LLC now owns 10,590 shares of the medical research company’s stock worth $1,112,000 after purchasing an additional 1,097 shares during the last quarter. California Public Employees Retirement System raised its position in Heska by 38.1% during the 1st quarter. California Public Employees Retirement System now owns 10,880 shares of the medical research company’s stock worth $1,142,000 after purchasing an additional 3,000 shares during the last quarter. Vanguard Group Inc. raised its position in Heska by 47.0% during the 1st quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after purchasing an additional 112,115 shares during the last quarter. Geode Capital Management LLC raised its position in Heska by 9.3% during the 1st quarter. Geode Capital Management LLC now owns 54,081 shares of the medical research company’s stock worth $5,677,000 after purchasing an additional 4,623 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Heska during the 1st quarter worth $5,853,000. Institutional investors own 81.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/heska-hska-earns-buy-rating-from-raymond-james-financial.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.